Therapeutic efficacy and safety of artemether-lumefantrine combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria at Teda Health Centre, Northwest Ethiopia, 2022/23.

Publisher: BioMed Central Country of Publication: England NLM ID: 101139802 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2875 (Electronic) Linking ISSN: 14752875 NLM ISO Abbreviation: Malar J Subsets: MEDLINE

Original Publication: London : BioMed Central, [2002-

Malaria, Falciparum*/drug therapy ; Artemether, Lumefantrine Drug Combination*/therapeutic use ; Artemether, Lumefantrine Drug Combination*/adverse effects ; Antimalarials*/therapeutic use ; Antimalarials*/adverse effects ; Antimalarials*/administration & dosage; Ethiopia ; Humans ; Male ; Female ; Adult ; Prospective Studies ; Adolescent ; Young Adult ; Middle Aged ; Child ; Child, Preschool ; Plasmodium falciparum/drug effects ; Drug Combinations

Background: The emergence of Plasmodium falciparum drug resistance against artemisinin-based combination therapy has threatened malaria control efforts. Since malaria control and elimination plans are dependent on these drugs, they must remain efficacious. However, resistance to these drugs was detected in low-transmission settings and is predicted to emerge in high-transmission settings, including in unspecified areas of Ethiopia. Therefore, this study aimed to assess the therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated P. falciparum malaria.
Methods: A single-arm prospective observational study was conducted at Teda Health Centre, Northwest Ethiopia, by following the 2009 World Health Organization efficacy study guidelines from September 2022 to February 2023. Patients with uncomplicated falciparum malaria were conveniently selected and treated with a standard dose of artemether-lumefantrine, along with a single low dose of primaquine. Then clinical and parasitological responses and haemoglobin levels were assessed during the 28-day scheduled follow-up. Blood films were examined and asexual parasites were quantified; axillary temperature was measured; and drug adverse events were assessed throughout the follow-up. Finally, the drug efficacy (adequate clinical and parasitological response) was determined by Kaplan-Meier and per-protocol analyses. The data were analysed using the WHO Excel spreadsheet and SPSS version 25 software.
Results: The success rates of PCR uncorrected and corrected Kaplan-Meier analysis on day 28 were 95.8% (95% CI 87.5-98.6) and 97.3% (95% CI 89.4-99.3), respectively. The per-protocol PCR uncorrected and corrected adequate clinical and parasitological responses were 95.5% (95% CI 87.5-99.1) and 97% (95% CI 89.5-99.6), respectively. On day-3, 97% of study participants were free of asexual parasitaemia, and all of them were fever-free on day-2. All of the gametocyte-positive patients at baseline were found to be negative for gametocytes on day-2. Moreover, the baseline mean hemoglobin of 13.10 g/dl increased slightly on day-14 to 13.27 g/dl but significantly on day-28 to 13.69 g/dl in a paired sample t test. All adverse events reported were mild.
Conclusion: Artemether-lumefantrine continued to be an efficacious and safe drug for the treatment of uncomplicated Plasmodium falciparum malaria at the Teda Health Centre.
Trial Registration: unique ID# PACTR202309773069812 at https://pactr.samrc.ac.za on September 1, 2023.
(© 2024. The Author(s).)

Lancet Infect Dis. 2021 Aug;21(8):1120-1128. (PMID: 33864801)
Elife. 2021 Jul 19;10:. (PMID: 34279219)
Parasit Vectors. 2010 Jan 5;3(1):1. (PMID: 20051120)
Malar J. 2023 Jan 7;22(1):9. (PMID: 36611179)
Malar J. 2011 Aug 10;10:231. (PMID: 21827706)
Epidemiol Infect. 2021 Jan 05;149:e27. (PMID: 33397548)
Malar J. 2021 Oct 13;20(1):401. (PMID: 34645475)
Lancet Infect Dis. 2015 Apr;15(4):415-21. (PMID: 25704894)
Ann Parasitol. 2018;64(1):49–57. (PMID: 29717574)
Malar J. 2015 Aug 15;14:317. (PMID: 26271736)
Am J Trop Med Hyg. 2016 Jan;94(1):132-5. (PMID: 26483118)
Malar J. 2023 May 13;22(1):154. (PMID: 37179349)
Malar J. 2018 Apr 3;17(1):144. (PMID: 29615039)
J Infect Dis. 2010 Feb 15;201(4):570-9. (PMID: 20085495)
J Infect Dis. 2009 Mar 1;199(5):758-65. (PMID: 19199542)
J Parasitol Res. 2022 May 24;2022:5170550. (PMID: 35656358)
BMC Infect Dis. 2017 Jun 23;17(1):443. (PMID: 28645255)
J Infect Dis. 2022 Apr 1;225(7):1215-1226. (PMID: 32778875)
Malar J. 2015 Jun 05;14:236. (PMID: 26045199)
PLoS Comput Biol. 2012;8(10):e1002729. (PMID: 23093922)
Trop Med Int Health. 2006 Dec;11(12):1800-7. (PMID: 17176344)
Int J Parasitol Drugs Drug Resist. 2021 Dec;17:186-190. (PMID: 34673330)
Methods Mol Med. 2002;72:103-16. (PMID: 12125106)
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0000222. (PMID: 35993723)
Malar J. 2019 Jun 24;18(1):209. (PMID: 31234865)
Am J Trop Med Hyg. 2003 Nov;69(5):558-63. (PMID: 14695097)
Malar J. 2015 Jun 24;14:258. (PMID: 26105035)
PLoS One. 2017 Apr 26;12(4):e0176004. (PMID: 28445503)
J Epidemiol Glob Health. 2022 Sep;12(3):362-371. (PMID: 35344160)
Malar J. 2020 Jul 10;19(1):240. (PMID: 32650784)
Malar J. 2020 Aug 27;19(1):304. (PMID: 32854686)
Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6958-63. (PMID: 20351286)
Malar J. 2024 Mar 9;23(1):71. (PMID: 38461239)
Nat Commun. 2022 Oct 26;13(1):6353. (PMID: 36289202)
Malar J. 2021 May 6;20(1):213. (PMID: 33957925)
Malar J. 2020 Jun 23;19(1):216. (PMID: 32576258)
Ther Clin Risk Manag. 2017 Feb 16;13:201-206. (PMID: 28243110)
Ther Clin Risk Manag. 2016 Aug 24;12:1293-300. (PMID: 27601913)
Lancet Infect Dis. 2022 Jun;22(6):867-878. (PMID: 35276064)
Malar J. 2019 Jan 18;18(1):11. (PMID: 30658632)
Malar J. 2018 Aug 2;17(1):279. (PMID: 30071877)

Keywords: Plasmodium falciparum; Artemether-lumefantrine; Efficacy; Malaria; Teda

0 (Artemether, Lumefantrine Drug Combination)
0 (Antimalarials)
0 (Drug Combinations)

Date Created: 20240830 Date Completed: 20240831 Latest Revision: 20240902

20240902

PMC11363363

10.1186/s12936-024-05082-y

39215366